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Abstract 
The incidence of inflammatory bowel diseases (IBD) - 
Crohn’s disease (CD) and ulcerative colitis (UC) - has 
been increasing on a global scale, and progressively, 
more gastroenterologists will be included in the 
diagnosis and treatment of IBD. Although IBD primarily 
affects the intestinal tract, extraintestinal manifestations 
of the disease are often apparent, including in the oral 
cavity, especially in CD. Specific oral manifestations 
in patients with CD are as follows: indurate mucosal 
tags, cobblestoning and mucogingivitis, deep linear 
ulcerations and lip swelling with vertical fissures. The 
most common non-specific manifestations, such as 
aphthous stomatitis and angular cheilitis, occur in 
both diseases, while pyostomatitis vegetans is more 
pronounced in patients with UC. Non-specific lesions in 
the oral cavity can also be the result of malnutrition and 
drugs. Malnutrition, followed by anemia and mineral 
and vitamin deficiency, affects the oral cavity and teeth. 
Furthermore, all of the drug classes that are applied to 
the treatment of inflammatory bowel diseases can lead 
to alterations in the oral cavity due to the direct toxic 
effects of the drugs on oral tissues, as well as indirect 
immunosuppressive effects with a risk of developing 
opportunistic infections or bone marrow suppression. 
There is a higher occurrence of malignant diseases 
in patients with IBD, which is related to the disease 
itself and to the IBD-related therapy with a possible 
oral pathology. Treatment of oral lesions includes 
treatment of the alterations in the oral cavity according 
to the etiology together with treatment of the primary 
intestinal disease, which requires adequate knowledge 
and a strong cooperation between gastroenterologists 
and specialists in oral medicine. 
Key words: Crohn’s disease; Ulcerative colitis; Drug-
related side effects and adverse reactions; Inflammatory 
bowel disease; Extraintestinal manifestations; Malnutrition 
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Oral pathology in inflammatory bowel disease
2016 Inflammatory Bowel Disease: Global view
Core tip: Inflammatory bowel diseases (IBD), Crohn’s 
disease (CD) and ulcerative colitis affect the intestinal 
tract, but can also present with extraintestinal 
manifestations and complications. In CD, disease-
specific lesions with granulomatous changes can 
occur in the oral cavity. However, non-specific lesions 
are more common in IBD and are mostly caused by 
malnutrition and medications. All of the drug classes 
that are applied in the treatment of IBD can lead to 
lesions in the oral cavity. This paper offers an overview 
of the oral pathology with a detailed description of the 
complications related to malnutrition and IBD therapy. 
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INTRODUCTION 
Crohn’s disease (CD) and ulcerative colitis (UC) belong 
to the group of chronic inflammatory bowel diseases 
(IBD). Although the etiology of these diseases has not 
been completely ascertained, it is well known that the 
factors contributing to disease pathogenesis include 
environmental aspects, intestinal microflora, genetic 
predisposition and pathological immune responses[1-3]. 
North America and North-Western Europe exhibit 
the highest incidence and prevalence of the disease, 
but an increase in the number of patients has been 
observed worldwide, indicating its emergence as a 
global disease[4,5]. It appears that the global increase in 
the disease is related to a “Western” lifestyle and diet, 
which shows the strong impact of the environment on 
the occurrence of the disease[1,3,6]. 
In addition to affecting the intestinal tract, the 
disease can manifest with extraintestinal symptoms in 
almost every organ system and significantly influence 
the quality of life and the functional state of the 
patient. There is a distinction between extraintestinal 
manifestations (EIM) and extraintestinal complications, 
although they are sometimes difficult to distinguish. 
EIMs occur in 6% to 47% of patients[7-10] with different 
rates of occurrence in relation to the primary disease. 
Peripheral arthropathy type I, aphthous stomatitis, 
erythema nodosum and episcleritis are usually related 
to an active disease. Ankylosing spondylitis and 
peripheral arthropathy type II have their own course 
of disease, independent of the activity of the bowel 
disease. Primary sclerosing cholangitis, uveitis and 
pyoderma gangrenosum have a variable course and 
can be associated with, but do not have to be related 
to, the activity of the bowel disease[10]. Patients with 
perianal CD, patients with colonic disease and smokers 
are at an increased risk of developing EIMs[9,10]. 
Furthermore, patients can develop several EIMs at the 
same time, and the occurrence of one EIM increases 
the risk of developing another EIM[10]. 
The pathogenesis of EIMs is still not fully identified. 
It appears that the inflamed intestinal mucosa can 
trigger immunological responses by sharing common 
epitopes (e.g., intestinal bacteria and synovia). Bacteria 
that can translocate because of greater permeability 
of the intestinal mucosa trigger an acquired immune 
response that does not distinguish between a bacterial 
epitope and a joint or skin epitope[10]. In patients with 
extraintestinal disease manifestations, there is also a 
strong genetic predisposition; the connection between 
the EIMs and the major histocompatibility complex loci 
has been demonstrated, and there is a concordance 
for EIMs in 84% of siblings[8,9]. 
Extraintestinal complications of inflammatory bowel 
diseases frequently occur due to malnutrition, chronic 
inflammation and side effects of drugs[2,8-10]. 
Oral lesions are common in patients with IBD and 
epidemiology data vary over a wide range of 5%-50% 
due to contradictory studies[11,12]. The goal of our paper 
is to present the oral pathology of IBD, whether it 
includes extraintestinal manifestations of the disease 
or its complications. 
ORAL MANIFESTATIONS OF 
INFLAMMATORY BOWEL DISEASE
Oral manifestations of CD include specific and non-
specific lesions, while in patients with UC, only non-
specific lesions in the oral cavity are observed. 
Characteristics of specific lesions include the presence 
of non-caseous granulomas, which occur only in CD 
patients. CD manifestations in the oral cavity can 
precede the intestinal manifestations, occur at the 
same time as the intestinal manifestations or occur 
after the occurrence of the intestinal manifestations. 
Oral lesions can be of significance when diagnosing 
CD because of a characteristic non-caseous granu-
lomatous inflammation[12-17]. This condition can be 
easily confirmed by a histopathological examination 
of accessible lesions in the oral cavity. Turchi et al[18] 
described a rare case of tonsillar granuloma as a 
manifestation of CD. Oral manifestations of the disease 
are more common in males[15,19,20] and children[12,19,21,22]. 
They are also more common in patients with CD 
than in patients with UC[23,24], and their prevalence 
in CD patients ranges from 20%-50%[11], while in 
UC the prevalence is 8%[25]. However, some studies 
have not demonstrated a statistically significant 
difference[26]. Furthermore, data from the literature are 
contradictory; in some studies, it has been stated that 
the changes in the oral cavity are not related to the 
CD activity index[27] or to the localization of intestinal 
manifestations[23,24,28,29], although there are papers that 
do link and attribute the changes in the oral cavity to 
inflammatory responses following the exacerbation of 
CD[26,30].
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Specific oral lesions in patients with CD include 
a cobblestone appearance of the oral mucosa; deep 
linear ulcerations; mucosal tags; swelling of the 
lips, cheeks and face; lip and tongue fissures; and 
mucogingivitis[15,19,21,22,25,31]. The mucosa of the oral 
cavity is hyperplastic and resembles a “cobblestone”, 
which marks the nodular, granulomatous swelling of 
the oral mucosa (Figure 1). In addition, there are also 
indurated polypoid fringe-like lesions of the vestibule 
and the retromolar region. Mucosal tags and deep 
ulcerations with hyperplastic edges, firm or boggy to 
palpation, are mostly present in the labial and buccal 
mucosa and in retromolar regions. Attached gingiva 
and alveolar mucosa become swollen, granulated 
and hyperplastic with or without ulcerations[19,32]. 
Edema of the face, of one or both lips and of the 
buccal mucosa may also occur. This condition is 
unpleasant for patients because it can lead to facial 
deformation[15,19,22,25]. Non-caseous granulomatous 
inflammation[33] can be histologically detected in such 
lesions. The lips are the most commonly affected, 
and they are usually painless, tender and firm to 
palpation[34]. Numerous patients with swollen lips 
also develop painful vertical fissures where many 
microorganisms can be isolated[35]. 
Furthermore, patients with CD often experience 
autoimmune changes of the minor salivary glands and 
dry mouth[23,36]. Mills et al[36] reported a case of patient 
with CD in which characteristic granulomatous lesions 
caused rupture of the excretory salivary duct leading 
to the formation of a cutaneous salivary duct fistula. 
Chronic inflammatory processes near the parotid duct 
resulted in partial to total duct obstruction and caused 
dilated ducts and cyst formation, which can lead to the 
formation of cutaneous fistula. All of these changes 
can cause reduction in saliva and dry mouth[23].
Non-specific oral lesions associated with CD 
and UC include aphthous stomatitis, angular che-
ilitis, pyostomatitis vegetans, glossitis and lichen 
planus[13,17,19,23,31,37,38]. Non-specific lesions, present 
in both CD and UC patients, are more common than 
specific lesions, which makes the differential diagnosis 
very difficult[13]. Non-specific lesions occur due to 
chronic inflammation, malnutrition and as a side effect 
of drugs. The occurrence of halitosis[23], dental erosion, 
dental caries[20,30,39,40], candidiasis, odynophagia and 
dysphagia[23,26] is more common in patients with IBD 
than in the general population. Furthermore, patients 
with UC exhibit diffuse pustules and non-specific 
gingivitis in the oral cavity[19]. 
Aphthous stomatitis, which occurs in both CD 
and UC patients, presents as shallow, round ulcers 
surrounded by an erythematous “halo” with a central 
fibrin membrane[19,31]. Aphthous stomatitis does not 
differ from the stomatitis that occurs in the general 
population. If aphthous ulcerations are present, the 
presence of inflammatory bowel disease must be 
suspected, although intestinal symptoms may not 
yet be present[28,29]. Because oral lesions are more 
common in children and can precede the development 
of inflammatory bowel disease, cooperation between 
a specialist in oral medicine and a gastroenterologist is 
crucial to detect the disease as early as possible[12,13]. 
Angular cheilitis is clinically manifested as erythema 
with or without painful fissures and sores at the 
corners of the mouth. It can occur due to anemia or as 
a manifestation of a fungal or bacterial infection[25,41-43]. 
Pyostomatitis vegetans is a rare benign chronic 
inflammatory mucocutaneous disorder characterized 
by pustules of an unknown etiology. It is related to 
inflammatory bowel disease, occurs more often in 
combination with UC (although it can occur in CD) 
and is more common in male patients. It represents a 
specific inflammatory marker of UC[19,33]. Only about 
fifty cases of this disorder have been described to-
date[37,38,44-50]. Macroscopically, the disease manifests 
as small exophytic lesions with an erythematous 
perimeter and a creamy white or yellow surface. 
They are covered with vulnerable membranes and 
their cracking results in small superficial erosions or 
ulcers. The confluence of those lesions results in the 
characteristic morphology sign of a “snail track”[33]. 
The alterations occur in the upper and lower frontal 
vestibule, on the tongue (Figure 2) and gingiva, as well 
as on the soft and hard palate[33]. Microscopically, there 
are no granulomas in the lesions.
Although IBD complications lead to non-specific 
lesions in the oral cavity, the consequences of two 
of the most common complications, malnutrition 
and medications administered for the treatment of 
inflammatory bowel disease, must be emphasized. 
Table 1 summarizes the oral manifestations and 
complications of IBD.
ORAL PATHOLOGY CAUSED BY 
MALNUTRITION 
Malnutrition is present in 23% of outpatients and 85% 
of hospitalized patients suffering from IBD[51]. It is 
caused by a reduced food intake, reduced resorption of 
nutrients, gastrointestinal losses, increased metabolic 
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Figure 1  Cobblestoning and ulcerations in Crohn's disease.
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Table 1  Oral manifestations and complications in inflammatory bowel disease
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jejunum) lead to a microcytic, hypochromic anemia, 
while the presence of proinflammatory cytokines 
causes chronic anemia with a high hyperferritinemia. 
The deficiency of B12 and folates leads to macrocytic 
anemia. The deficiency of B12 occurs most often in 
Crohn’s disease due to reabsorption deficiency in the 
terminal ileum, while the deficiency of folates can be 
caused by reduced reabsorption, inadequate dietary 
intake and as a side effect of methotrexate and 
sulfasalazine[7,54]. 
Anemia caused by an iron deficiency is manifested 
as paleness of the oral mucosa[55], generalized oral 
mucosal atrophy, pricking[56,57], atrophic glossitis with 
tongue pain[57] and angular cheilitis[43,55]. The deficiency 
of vitamin B12 is manifested in the oral cavity as a 
painful atrophy of the oral mucosa and the tongue, 
recurrent aphthous ulcerations[58,59], angular cheilitis, 
oral candidiasis, diffuse erythematous stomatitis and 
pale yellowish mucosa, especially on the palate[60]. 
Patients can also complain of altered taste, a burning 
sensation in the mouth and dysphagia[43]. If anemia 
is caused by a folate deficiency, the manifestations 
in the oral cavity are the same as in anemia caused 
by vitamin B12 deficiency but without neurological 
symptoms[43]. In more severe cases, ulcerative sto-
matitis and pharyngitis[43] are also detected. 
needs and as a side effect of drugs[51,52]. As a result of 
a nutrient deficiency, patients develop anemia due to 
lower iron, vitamin B12 and folate levels. In addition to 
anemia, a deficiency of electrolytes, trace elements 
and vitamins is also quite common[52,53]. Anemia is a 
common complication of inflammatory bowel disease, 
which can be manifested in oral pathology. Suffering 
from anemia can strongly influence the patient’s quality 
of life. Bleeding and reduced iron reabsorption (due 
to inflammatory changes in the duodenum and upper 
Oral tissue Manifestations Etiology
Lips Lips swelling with or without fissures[12,15,16,21,22,34,36,156] Crohn's disease 
Angular cheilitis[15,22,31] Fungal and bacterial infections, nutritional deficiency 
Erythema multiforme, Stevens-Johnson syndrome[143,144] Infliximab; adalimumab
Tongue Fissuring[23] Crohn's disease
Cobblestone plaques[17] Crohn's disease
Pyostomatitis vegetans[17,37,38,45] Ulcerative colitis (more common) and Crohn's disease
Aphthous stomatitis[11,31] Nutritional deficiency; decreased heat shock protein 27 expression
Taste disturbance[17,23,147,155] Related to disease activity and nutritional habits; sulfasalazine; 
metronidazole 
Candida infections[78,131,132,141] Corticosteroids; thiopurines; cyclosporin A; infliximab 
Erythema multiforme, Stevens-Johnson syndrome[143,144] Infliximab; adalimumab
Oral mucosa Buccal edema[15,34,48] Crohn's disease
(labial/buccal/ Cobblestoning[12,14,15,21,24,34] Crohn's disease
palatal/vestibular) Deep linear ulceration[15,16,21-24,34,38] Crohn's disease
Mucosal tags[12,16,21,29,34] Crohn's disease
Buccal sulcus ulcerations[20,34] Crohn's disease
Palatal ulcerations[20,44] Crohn's disease
Pyostomatitis vegetans[33,37,45-47,49,50] Ulcerative colitis (more common) and Crohn's disease
Aphthous stomatitis[11,22,29,31,45] Nutritional deficiency; decreased heat shock protein 27 expression
Lichen planus/lichenoid reaction[29,85,140,142] Sulfasalazine; mesalazine; infliximab;
certolizumab pegol
Erythema multiforme, Stevens-Johnson syndrome[143,144] Infliximab; adalimumab
Periodontal tissue Mucogingivitis[12,21,22,32,34] Crohn's disease
Cobblestoning[29,32] Crohn's disease
Pyostomatitis vegetans/pustular ulcerations[17,32,33,37,44,46,50] Ulcerative colitis (more common) and Crohn's disease 
Nonspecific gingivitis[13,19,147] Cause not clearly specified
Periodontal diseases/periodontitis[20,156] Cause not clearly specified
Alveolar bone Periapical lesions[30] Related to disease activity
Alveolar bone loss[156] Cause not clearly specified
Teeth Caries[20,30,39,40] Related to disease activity and malabsorption
Hypoplasia of enamel[40] Related to disease activity and malabsorption
Salivary glands Hyposalivation/dry mouth[23,36] Granulomatous inflammation
Autoimmune changes in minor salivary glands
Salivary duct fistula[36] Crohn's disease
Figure 2  Pyostomatitis vegetans in ulcerative colitis.
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Today, it is well known that vitamin D not only 
plays an important role in the mineralization of 
bones and teeth but also contributes to numerous 
metabolic processes and has a protective role in 
immune-mediated diseases as well as allergies. 
A vitamin D deficiency, in addition to disorders in 
the metabolism of calcium and phosphate in the 
oral cavity, is accompanied by the development of 
bone hypomineralization and an increased risk of 
fractures[61]. Malabsorption of calcium, vitamin K 
and other nutrients, treatment with corticosteroids, 
inflammatory cytokines in IBD and hypogonadism 
caused by IBD are additional factors that contribute 
to the decreased bone mineral density[62]. A vitamin 
D deficiency is also associated with the increased 
prevalence of periodontal diseases (gingivitis and 
periodontitis), dental caries and tooth loss[63-65]. 
Vitamin D also exerts an immunomodulatory effect, 
and its deficiency increases the risk of infection, 
malignancy and autoimmune disease[66] with possible 
oral manifestations. Calcium is a mineral that 
plays an important role in tooth development and 
mineralization. Experimental studies have shown that 
a calcium deficiency causes a disorder affecting the 
mineralization of dentin and enamel[40,67]. A decreased 
mineralization of bones and teeth is expected in 
children, who have developed IBD with a deficiency 
of calcium and vitamin D. However, according to the 
literature, there are no studies addressing this issue. 
Vitamin A and vitamin C deficiencies are also 
described in IBD patients. A vitamin A deficiency 
is manifested in the oral cavity as angular cheilitis, 
atrophy and dryness of oral mucosa. The lips are 
described as “retreating” because the mucosa contracts 
towards the oral cavity[68]. A vitamin C deficiency is 
manifested in the oral cavity as generalized gingival 
swelling and spontaneous bleeding, ulcerations, tooth 
mobility, increased severity of periodontal infections 
and bone loss[55,69]. Spontaneous bleeding of the 
mucosa can be observed as well[70]. The development 
of bones and teeth is disrupted in children because 
both dentin and osteoid depend on vitamin C. 
A zinc deficiency is quite common in CD patients. 
It is manifested in the oral cavity with erosions, 
ulcers and fissures, a crusting and scaling rash on 
the lips[29,71],burning mouth syndrome[56] and altered 
taste[72]. 
ORAL PATHOLOGY CAUSED BY 
MEDICATION
Treatment of inflammatory bowel diseases includes 
5-aminosalicylic acid (5-ASA) derivatives, corticos-
teroids, immunomodulators, calcineurin inhibitors, 
biological therapy and antibiotics. The selection of 
treatment depends on the site of the disease, the 
disease activity and the course or behavior of the 
disease[73,74]. Currently, the personalized approach to 
therapy is advocated, and “risk matrices” for assessing 
the risk of developing severe forms of the disease have 
been developed[75,76]. The therapy applied to treating 
inflammatory bowel diseases can lead to alterations in 
the oral cavity due to the direct toxic effect of the drug 
on the oral tissue, the indirect immunosuppressive effect 
which increases the risk for opportunistic infections or 
bone marrow suppression. The immunomodulators 
commonly used in IBD treatment include the following: 
corticosteroids (a total dose equivalent to ≥ 20 mg of 
prednisolone for ≥ 2 wk), thiopurines, methotrexate, 
anti-tumor necrosis factor alpha (anti-TNF) agents 
and other biologics, which increase the risk of op-
portunistic infections[77]. The incidence of infection is 
higher if the patients simultaneously receive several 
immunosuppressive drugs, are malnourished, suffer 
from other associated diseases or have a prior history 
of serious infections[77-80]. The risk of infection also 
increases with age[77-79]. Potential myelotoxicity of the 
drugs, including the development of leucopenia and 
agranulocytosis, also increases the risk of developing 
opportunistic and serious infections[79-81]. In addition 
to the risk of developing gastrointestinal tumors, 
patients with inflammatory bowel diseases are at risk 
of developing hematological malignancies. Compared 
to the general population, patients suffering from 
CD are at risk of developing lymphoma, especially 
non-Hodgkin lymphoma, while patients with UC are 
more likely to develop leukemia[82]. Early disease 
onset, male gender and age > 65 are risk factors for 
developing hematological malignancies. With regard 
to malignancies related to IBD therapy, patients 
receiving thiopurines have an increased risk of 
developing cancer. The risk of developing lymphoma 
is also increased but can be reversed by thiopurine 
withdrawal. There is no evidence of an increased risk 
of developing cancer or lymphoma in patients who 
received monotherapy with anti TNF drugs[82]. 
Thus far, only one study addressing the risks of 
developing malignancies in the oral cavity of patients 
with IBD has been published[83]. Katsanos et al[83] have 
established that patients with IBD are at a higher risk 
of developing tumors in the oral cavity, especially on 
the tongue. The authors have also concluded that 
female IBD patients are at a higher risk than male 
patients. However, this study did not include a risk 
analysis based on the type of treatment. 
Oral complications of aminosalicylates 
Sulfasalazine has been used to treat UC for 50 
years[84]. It is a prodrug made of sulfapyridine and 
an active substance of 5-aminosalicylic acid (5-ASA). 
Sulfapyridine, or more precisely the sulfur component, 
is considered to be responsible for numerous side 
effects and allergic reactions caused by this drug. In 
the oral cavity, sulfasalazine causes an oral lichen 
planus/oral lichenoid reaction[85-87]. The occurrence of 
these lesions in the oral cavities of patients with IBD 
Muhvić-Urek M et al . Oral pathology in IBD
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is rare, and only a few cases have been described[85]. 
Some patients receiving sulfasalazine may complain 
of a metallic taste in the mouth[72]. Patients suffering 
from inflammatory bowel diseases who are receiving 
sulfasalazine can also develop oral complications 
caused by myelotoxicity and hepatotoxicity due to the 
sulfasalazine treatment, presented through signs of 
aplastic anemia, bleeding (ecchymosis and petechiae) 
and oral infections. Side effects of 5-ASA derivatives 
(non-sulfa-containing drugs) are less numerous[88] but 
have been described in the literature[89]. Mesalazine 
can cause hematological side effects, such as leu-
copenia, thrombocytopenia and aplastic anemia[89], 
resulting in alterations in the oral cavity. Alstead et 
al[85] presented a case of a patient who developed 
oral lichen as a reaction to sulfasalazine, which was 
replaced with mesalazine, but the lesions did not 
withdraw. After withdrawing the mesalazine, the oral 
lesions withdrew, and the authors concluded that the 
lesions were related to 5-ASA. 
Oral complications of corticosteroids
Despite their efficiency, corticosteroids were declared 
unsuitable for long-term use due to a high percentage 
of side effects (reported in 50% of patients)[90]. Early 
adverse effects in the orofacial region, which occur 
as a result of a supra-physiological dose, include 
acne, moon face, petechiae and ecchymosis due to 
blood vessel vulnerability[90-92]. The long-term use 
of corticosteroids increases the risk of opportunistic 
infection[78,79]. The risk of infection also depends on 
the dose[78]. The use of these drugs is related to the 
occurrence of candidiasis in the oral cavity, pharynx 
and esophagus[78]. Pseudomembranous candidiasis 
and chronic atrophic candidiasis are the most prevalent 
forms of oral candidiasis in such patients (Figure 3)[92,93]. 
Patients receiving corticosteroids and thiopurines 
simultaneously have an increased risk of developing 
opportunistic infections than patients who receive 
corticosteroids only[78]. Tourner et al[78] observed a 
10% prevalence of Candida albicans infections in 
patients with IBD receiving corticosteroid therapy 
only. However, the clinical site of these infections was 
not specified. Numerous case reports and clinical 
studies on primary varicella zoster virus and herpes 
zoster virus infections[78,79,81,94] in patients with IBD 
were published, but checking the literature, no papers 
on these infections occurring in the oral cavity and 
orofacial region have been published. Herpes simplex 
virus (HSV) infections in such patients are also 
common, whether they are of primary or recurrent 
character[78,95-98]. Tourner et al[78] have described an 
18% prevalence of HSV infections on the face, in the 
esophagus or on the extremities of patients with IBD. 
In children with IBD, especially with CD, the 
disease itself[99] and the use of corticosteroids[100] can 
affect growth. There are no studies analyzing bone 
development in the orofacial region of children with 
IBD, especially in children who have received long-
term corticosteroid therapy. Long-term corticosteroid 
use can also result in osteoporosis, affecting the 
patients’ jawbones and increasing the risk of peri-
odontal diseases and fractures. Experimental and 
clinical studies have shown that the long-term use of 
corticosteroids leads to the occurrence of calcifications 
in the dental pulp and pulp obliteration[101-103]. 
Oral complications of thiopurines 
Azathioprine (AZA) and 6-mercaptopurine (6-MP) are 
thiopurine drugs that have been used in the treatment 
of IBD for the past 50 years, primarily for the 
maintenance of disease remission[90]. Unfortunately, 
in addition to the beneficial treatment effects in 
some patients with IBD, these drugs can also cause 
complications and lead to adverse effects. AZA has 
been shown to cause taste disturbances in the form 
of ageusia/hypogeusia and dysgeusia[72]. Other side 
effects of thiopurines include opportunistic infections, 
myelotoxicity and hepatotoxicity as well as a risk of 
developing malignant lymphomas, which can also 
lead to alterations in the oral cavity. The use of AZA/6-
MP increases the risk of opportunistic infections for 
patients taking steroids from approximately 2-3-fold 
to approximately 15-fold[78]. Atypical clinical features 
and longer disease duration are characteristics of these 
infections. Cases of recurrent HSV infections with large 
and irregular ulcerations occurring in any region of the 
Figure 3  Pseudomembranous candidiasis on the palatal mucosa and 
atrophic candidiasis on the tongue in a Crohn's disease patient treated 
with anti-TNF and prednisone.
Muhvić-Urek M et al . Oral pathology in IBD
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oral mucosa and lasting for weeks or months have 
been described. The lesions can also occur on non-
keratinized mucosa (a region not usually affected) and 
are not easily distinguished from aphthous lesions[104]. 
Due to a potential myelotoxic effect of thiopurines, 
such as the development of leucopenia and neu-
tropenia[105,106], the risk of developing opportunistic 
infections is increased. 
It is well known that the use of thiopurines increases 
the risk of developing lymphoma and cancer[82,107,108]. 
However, clinical studies on the prevalence of malignant 
diseases in the oral cavity of patients with IBD receiving 
thiopurines are lacking. Only one clinical study was 
published on this subject. Pasternak et al[109] established 
that patients with IBD who are receiving thiopurines 
are at no greater risk of developing lip, oral cavity or 
pharynx cancer. Dojcinov et al[110] were the first to 
present the cases of two rheumatoid arthritis (RA) 
patients with an azathioprine-related lymphoproliferative 
disorder (LPD) in the oral cavity. 
Oral complications of methotrexate 
Methotrexate is a stomatotoxic drug, which causes oral 
ulcers, ulcerative stomatitis and mucositis[87,111-113]. The 
occurrence of lesions in the oral cavity is associated with 
a folic acid deficiency and toxic effects of the drug[112]. 
The effects of the drug in the oral cavity depend on 
the administered dose. Lower doses cause ulcers and 
stomatitis, while higher doses, administered to treat 
malignant diseases, cause mucositis[114]. Several clinical 
studies and cases have described oral ulcers, stomatitis 
and mucositis in patients treated with methotrexate due 
to RA, psoriasis and malignancies[113,115,116]. Furthermore, 
methotrexate can cause agusea/hypogeusia in the 
oral cavity[72]. However, there are no published pa-
pers on the occurrence of oral ulcers, stomatitis and 
taste disturbances in patients with IBD treated with 
methotrexate. 
Bone marrow suppression (in the form of leu-
copenia, thrombocytopenia or pancytopenia) is also 
described in patients receiving methotrexate (more 
often in patients treated with high doses and less 
often in patients treated with low doses)[117,118]. Oral 
alterations can develop as a consequence of bone 
marrow suppression. The only study on oral infections 
in patients receiving low doses of methotrexate that 
we found was published by Pedrazas et al[119]. The 
authors described a significantly higher prevalence 
of oral candidiasis (10.7%) and oral ulcers (60.7%) 
in patients with RA receiving methotrexate than in 
patients who were not treated with methotrexate. 
Several clinical cases of methotrexate-related 
Epstein-Barr virus associated lymphoproliferative 
disorders in the oral cavity in patients with RA and Still’s 
disease[110,111,120-126] have been published. Clinical LPD is 
manifested in the oral cavity as swelling or painful ulcers 
of irregular edges on the gingiva, tongue, floor of the 
mouth and buccal mucosa[110,111,120-126]. In some cases, 
the bone[111,122,125] was also affected. The common 
characteristic of these disorders is that the majority 
of lesions regress completely following the withdrawal 
of methotrexate[123]. According to the literature, there 
are no descriptions of these disorders in the oral cavity 
caused by methotrexate in patients with IBD. 
Oral complications of calcineurin inhibitors 
(cyclosporine and tacrolimus) 
Gingival hyperplasia (or gingivae overgrowth) is 
common in patients receiving cyclosporine (CsA). 
The severity of gingival hyperplasia depends on the 
duration of CsA therapy, but its occurrence is also 
influenced by bacterial plaque, local irritants and 
possibly the simultaneous use of other drugs that 
cause gingival hyperplasia (e.g., nifedipine)[127,128]. 
Gingival hyperplasia can interfere with oral functions 
and speech and can cause delayed and/or ectopic 
dentition and difficulties in maintaining oral hygiene, 
increasing the risk of caries, infection and periodontal 
disease[129]. 
Furthermore, in patients receiving CsA, filiform 
papillae hypertrophy on the tongue[130], opportunistic 
infections (candidiasis)[131,132], squamous-cell carcinomas 
on the lip[133], non-Hodgkin lymphomas[134,135] and lymph-
oproliferative disorders[110,136,137] have been described in 
the oral cavity. The side effects of tacrolimus are less 
common compared to cyclosporine[138], and currently 
there is no evidence of complications associated with 
tacrolimus treatment in the oral cavity. 
Oral complications of biologic drugs
In addition to exerting a revolutionary effect in treating 
inflammatory bowel diseases, TNF alpha inhibitors have 
numerous side effects. These drugs can cause oral 
lichen/lichenoid reactions and opportunistic infections 
in the oral cavity[87,139-142]. Asarch et al[139] reported 
two cases of oral lichenoid reaction in patients with 
psoriasis receiving infliximab and adalimumab. Moss 
et al[140] described a case of a patient with CD receiving 
infliximab that resulted in an oral lichenoid reaction. 
Cases of erythema multiforme and Stevens-Johnson 
syndrome in the oral cavity and on the skin in patients 
with CD receiving infliximab and adalimumab[143,144] 
were also reported. Oral opportunistic infections 
(primarily candidiasis) can be expected in patients 
with IBD treated with anti-TNF drugs but so far only 
one case report has been published[141]. There are no 
clinical studies on the prevalence of opportunistic oral 
infections in these patients. One of the most often 
described side effects of vedolizumab (a gut selective 
anti-integrin) is pharyngitis[145,146].
Oral complications of antibiotics (metronidazole and 
ciprofloxacin) 
The most common side effect of metronidazole is 
a metallic taste in the mouth[147]. In addition to the 
metallic taste, there are no other described side effects 
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of these antibiotics in the oral cavity. 
TREATMENT OF THE ORAL LESIONS 
The goal of treating oral lesions in patients with IBD is 
to reduce pain, accelerate the healing of lesions and 
prevent secondary infections. The treatment depends 
on the etiology, severity of the clinical presentation and 
the symptoms of the oral lesions. Treatment options 
include topical or/and systemic medications. Although 
the first European evidence-based consensus on 
extraintestinal manifestations in inflammatory bowel 
disease has been recently published[148], there are still 
no statements on the treatment of oral manifestations 
and complications of IBD.
Treatment of specific oral lesions in Crohn’s disease 
and pyostomatitis vegetans (which occur in both 
diseases) is always aimed at treating and controlling 
the underlying disease, and lesions usually respond 
well to IBD treatment[37-39,41-43,46,50]. In addition to 
systemic therapy, topical agents can be used; therefore, 
a multidisciplinary approach is essential. Topical 
treatments include steroids (topical or intralesional 
injections), topical tacrolimus, 5-ASA mouthwashes, 
topical anesthetics for pain relief, non-steroidal anti-
inflammatory pastes and antiseptic mouthwash for 
preventing secondary infections[11,14,19,33,34,149]. 
In IBD patients, the treatment of aphthous stomatitis 
includes nutrition supplements and topical or systemic 
medication therapy. The choice of therapy depends on 
the severity of symptoms and the type and numbers of 
aphthous lesions. Choices for therapy include steroids 
(topical, intralesional or systemic) as a first line of 
treatment, topical anesthetics, antiseptic mouthwash or 
non-steroidal anti-inflammatory pastes[150]. Furthermore, 
non-medical treatments, such as ozone therapy and 
low-level laser therapy, can be used for pain relief and 
to accelerate lesion healing[151,152]. When the aphthous 
lesions are numerous and very painful, systemic 
steroids, immunosuppressive agents and thalidomide 
are indicated[11,150].
Angular cheilitis and glossitis are frequently 
caused by anemia and malnutrition; in cases with 
specific deficiencies, the replacement of iron, B12, 
folate and zinc is necessary[52-54]. Angular cheilitis can 
also be caused by fungi (Candida spp.) and bacteria 
(Staphylococcus aureus or b-hemolytic streptococci). 
In the case of fungal etiology, treatment options 
include topical antifungals (e.g., nystatin, miconazole, 
ketoconazole or clotrimazole). When the infection is 
caused by Staphylococcus aureus, topical treatments 
include combinations of mupirocin or fusidic acid and 
1% hydrocortisone cream[153]. 
Most often, oral infections occur as a consequence 
of immunosuppressive drug therapy, and candidiasis is 
the most commonly occurring infection. Oral candidiasis 
does not require the interruption of therapy[77]. Topical 
therapy options include nystatin, amphotericin B, 
miconazole, fluconazole, ketoconazole or clotrimazole. 
In some cases, systemic therapy with fluconazole, 
itraconazole or ketoconazole is necessary[154].
HSV infection is not a contraindication for immuno-
suppressive therapy. In recurrent oral HSV infections, 
oral antiviral therapy should be considered[77].
When oral lichen/oral lichenoid reactions or taste 
disturbances are present, the interruption and re-
placement of medication can be considered. 
The occurrence of erythema multiforme or Stevens-
Johnson syndrome requires the prompt interruption 
of biologic drugs[143,144]. The patients with erythema 
multiforme can be treated as out-patients with 
systemic and topical steroids[143]. Stevens-Johnson 
syndrome requires treatment in a hospital setting[144]. 
CONCLUSION
Oral lesions in patients with inflammatory bowel 
disease can be extraintestinal manifestations of the 
disease or can occur as complications of the disease 
and treatment. They occur more often in CD patients 
than in UC patients, although pyostomatitis vegetans is 
more common in UC patients. One or more oral lesions 
can simultaneously appear in the oral cavity. The 
severity of their clinical presentation can range from 
mild and painless to extensive and painful. The lesions 
can compromise oral functions. Cooperation between 
specialists in oral medicine and gastroenterologists is 
essential for the successful diagnosis of IBD (in cases 
when oral pathology precedes intestinal manifestations), 
as well as in the diagnosis and treatment of oral lesions 
in such patients.
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